Corcept Therapeutics Inc SEC Filings

William Guyer, Chief Development Officer of Corcept Therapeutics (CORT) reported insider transactions dated 08/08/2025. The Form 4 shows derivative and non-derivative activity executed pursuant to a 10b5-1 plan adopted on 11/27/2024. The filing reports acquisition in Table II of a stock option granting the right to buy 35,007 shares with an exercise price of $21.65; that option is shown as fully exercisable and carries an expiration date of 09/01/2031. Table II lists 350,000 derivative securities beneficially owned following the reported transaction.

Table I records non-derivative movements on the same date, including a reported disposition coded S of 35,007 common shares at a price of $71.77. The two Table I lines display reported beneficial ownership amounts of 40,494 and 5,487 shares respectively after the reported transactions. The Form notes the 10b5-1 plan governed the transactions.

Corcept Therapeutics (CORT) filed a Form 144 reporting an intended sale of 2,200 common shares through Fidelity on NASDAQ with an aggregate market value of $159,060. The filing lists total shares outstanding of 105,371,729, showing the proposed block represents a very small fraction of outstanding stock.

The securities are shown as acquired in connection with an option granted 08/20/2018 and the filing indicates acquisition and proposed sale activity on 08/11/2025 for cash. The filer, Daniel Swisher, also reported three prior sales in the past three months (2,200 shares each on 05/12/2025, 06/10/2025 and 07/10/2025) with listed gross proceeds for each sale.

On 08/05/2025, Corcept Therapeutics (CORT) Chief Development Officer William Guyer filed a Form 4 detailing a tiny, Rule 10b5-1-planned transaction. He exercised 14 stock options at an exercise price of $21.65 (code M) and immediately sold the same 14 common shares at $71.77 (code S). After the trades, Guyer directly holds 5,487 common shares and still owns 385,007 unexercised options expiring 09/01/2031.

The gross sale proceeds are roughly $1,000, an amount immaterial relative to Corcept’s market cap and Guyer’s remaining equity stake. No other insider activity or company developments are disclosed. Given the de-minimis size and pre-arranged nature, the filing is unlikely to influence investor sentiment or signal a change in management’s outlook.

Corcept Therapeutics (CORT) – Form 4 filing, 08/05/2025: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,823 employee stock options at an exercise price of $13.56 (cost ≈ $79k) and immediately sold the same 5,823 shares under a pre-arranged 10b5-1 plan at a weighted-average $67.5129, generating gross proceeds of ≈ $393k and a spread of ≈ $314k before taxes.

Following the transactions Lyon directly owns 10,066 CORT common shares, including 1,552 unvested RSAs that vest one year from their respective grant dates, and retains 31,571 vested options. No other classes of securities were affected. The transaction neither alters total shares outstanding nor signals corporate fundamentals, but it represents a partial monetisation by a senior officer at ~5× the option strike.

Corcept Therapeutics Inc. (CORT) filed a Form 144 indicating that William Guyer intends to sell up to 20,000 common shares through broker Stifel Nicolaus on or about 08/05/2025. The shares have an estimated aggregate market value of $1.44 million, based on recent market prices. Corcept has 106.04 million shares outstanding, so the planned sale represents roughly 0.02% of total shares.

The filing also discloses that Guyer has already sold 64,301 shares in the past three months, generating $4.73 million in gross proceeds across six transactions. The forthcoming sale continues this selling trend but remains immaterial in size relative to total float. No pricing, earnings, or operational data are provided in the notice, and the signer affirms no undisclosed adverse information.

Corcept Therapeutics Inc. (CORT) – Form 144 filing discloses a proposed sale of 5,000 common shares by shareholder Joseph D. Lyon. The shares will be routed through Stifel Nicolaus & Co. on the NASDAQ with an estimated aggregate market value of $335,850 (based on the indicated $67.17 reference price). The company has 106.04 million shares outstanding, so the planned sale represents roughly 0.005 % of total shares.

The filer reports additional sales over the past three months totaling 18,527 shares for gross proceeds of $1.37 million. When combined with the proposed sale, Lyon’s total disposition for the rolling three-month window would reach 23,527 shares (~0.022 % of shares outstanding).

No purchase price was deferred; the 5,000 shares were acquired via stock-option exercise on 08/01/2025 and will be sold for cash. The filing contains the standard representation that the seller is unaware of undisclosed material adverse information and does not reference a Rule 10b5-1 plan.

Given the small size relative to the public float and absence of additional corporate disclosures, the filing appears routine and is unlikely to have a material impact on CORT’s valuation or trading dynamics.

Corcept Therapeutics (CORT) – Form 144 filing. President Sean Maduck has filed to sell 20,000 common shares through broker Stifel Nicolaus on or about 01 Aug 2025. At the 07/31/25 reference price, the sale is valued at $1.34 million. The shares were just acquired the same day via stock-option exercise; therefore the transaction is likely part of routine option monetisation.

Maduck has already disposed of 64,403 shares during the past three months for ~$4.79 million in gross proceeds. After the proposed trade, cumulative sales disclosed in the filing period reach ~84 k shares. CORT has 106.04 million shares outstanding, making the new sale ~0.02 % of outstanding stock and therefore not materially dilutive. No earnings, guidance or operational data are provided; this notice is strictly an insider-sale disclosure.